TDO as a therapeutic target in brain diseases
Cheng-Peng Yu1, Ze-Zheng Pan2, Da-Ya Luo3
1The Second Clinic Medical College, School of Medicine, Nanchang University, Nanchang, China.
Metabolic Brain Disease
|April 14, 2016
Summary
Tryptophan-2,3-dioxygenase (TDO) impacts brain health by altering tryptophan levels. This review explores TDO
Area of Science:
- Biochemistry
- Neuroscience
- Immunology
Background:
- Tryptophan-2,3-dioxygenase (TDO) catalyzes tryptophan to kynurenine (KYN), impacting neurotransmitter levels.
- TDO activation depletes tryptophan and increases KYN, affecting neuronal function and T cell proliferation.
- TDO is implicated in brain diseases, cancer, and transplantation, making it a therapeutic target.
Purpose of the Study:
- To provide a comprehensive review of TDO, covering its biology, evolution, structure, and catalytic mechanisms.
- To examine the role of TDO in the pathology of schizophrenia, Alzheimer's disease (AD), and glioma.
- To discuss future directions for TDO research in brain diseases and the development of TDO inhibitors.
Main Methods:
- Literature review and synthesis of existing research on TDO.
- Analysis of TDO's involvement in the pathophysiology of specific neurological disorders.
- Exploration of TDO inhibitor development and therapeutic applications.
Main Results:
- TDO's enzymatic activity influences tryptophan metabolism and downstream signaling pathways.
- Dysregulation of TDO is linked to the pathogenesis of schizophrenia, AD, and glioma.
- TDO inhibitors show potential for treating TDO-related neurological conditions.
Conclusions:
- TDO is a critical enzyme in tryptophan metabolism with significant implications for brain health.
- Targeting TDO offers a promising therapeutic strategy for various brain diseases.
- Further research into TDO's role in other neurological disorders and inhibitor development is warranted.
More Related Videos
![Radiosynthesis of 1-2-[18F]Fluoroethyl-L-Tryptophan using a One-pot, Two-step Protocol](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F63025.jpg&w=3840&q=50)
08:33Radiosynthesis of 1-2-[18F]Fluoroethyl-L-Tryptophan using a One-pot, Two-step Protocol
Published on: September 21, 2021
3.7K
10:38Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures
Published on: May 9, 2020
3.8K
Related Concept Videos
01:29Drugs Affecting Neurotransmitter Synthesis
2.5K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
65
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
01:29Pharmacogenomics: Identification of New Drug Targets
75
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
75
01:26Targets for Drug Action: Overview
11.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.2K
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
01:16Therapeutic Drug Monitoring: Overview and Classification
505
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
505